PASS-01 Announcement: A Message from Michelle Capobianco

PASS-01 Announcement: A Message from Michelle Capobianco

Today I am thrilled to announce the launch of our next landmark research investment, PASS-01: a clinical trial that will finally address the diverse nature of this disease and provide personalized treatment options for advanced pancreatic cancer patients. For over 40...
Alex Trebek’s Death and the Need for Reseach

Alex Trebek’s Death and the Need for Reseach

Alex Trebek’s Death and the Need for Innovative Research: 900CHML Pancreatic Cancer Canada CEO Michelle Capobianco speaks with 900CHML host Scott Thompson about Alex Trebek’s passing to stage IV pancreatic cancer, the need for public awareness and...
NeoPancONE Announcement: A Message from Michelle Capobianco

NeoPancONE Announcement: A Message from Michelle Capobianco

For several months the COVID-19 crisis has caused many research projects to slow, but Pancreatic Cancer Canada’s research program has not been idle. We have taken this time to quietly prepare for our next big project, because even in the midst of...
PRESS RELEASE: NeoPancONE Clinical Trial Launch

PRESS RELEASE: NeoPancONE Clinical Trial Launch

Pancreatic Cancer Clinical Trial Launches During Pandemic With Aim to Change Standard of Care for Patients TORONTO, ON, July 15, 2020 – Pancreatic Cancer Canada announced today the launch of NeoPancONE, a Phase II clinical trial that aims to be a curative strategy for...